In one paragraphArticle in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
18 authors.
Na Li *Hematologic Disease Laboratory, Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education; Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.ORCID https://orcid.org/0000-0002-3920-513X Ying Yang *Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education; Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.ORCID https://orcid.org/0000-0001-7111-3641 Hongyun LianHematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education; Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.ORCID https://orcid.org/0009-0005-2413-8084 Honghao MaHematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education; Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.ORCID https://orcid.org/0009-0006-0675-3478 Yali LiuCenter for Clinical Epidemiology and Evidence-based Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.ORCID https://orcid.org/0000-0003-0037-6326 Xiaolu NieCenter for Clinical Epidemiology and Evidence-based Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.ORCID https://orcid.org/0000-0001-8026-7845 Dong WangHematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education; Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.ORCID https://orcid.org/0009-0001-5520-8867 Li ZhangHematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education; Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.ORCID https://orcid.org/0009-0006-6116-0317 Ang WeiHematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education; Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.ORCID https://orcid.org/0000-0002-7046-2417 Lei CuiHematologic Disease Laboratory, Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education; Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.ORCID https://orcid.org/0000-0002-7611-1431 Liping ZhangHematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education; Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.ORCID https://orcid.org/0000-0002-5364-5780 Wenxin OuHematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education; Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.ORCID https://orcid.org/0000-0001-9929-5619 Tianyou WangHematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education; Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.ORCID https://orcid.org/0000-0002-8641-3046 Zhigang LiHematologic Disease Laboratory, Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education; Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.ORCID https://orcid.org/0000-0001-5334-9706 Rui ZhangHematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education; Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.ORCID https://orcid.org/0000-0002-3727-1192 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Background: A portion of children with Langerhans cell histiocytosis (LCH) exhibit recurrent or persistent disease-related fever at their first visit. We aimed to clarify the clinical characteristics, laboratory indicators, prognostic differences, and optimal regimens for these children with fever. Methods: A cross-sectional design (single-center, retrospective, and observational) was adopted for this study. A total of 448 pediatric patients diagnosed with LCH in our hospital from January 2016 to December 2019 were retrospectively enrolled and divided into two groups: children with fever (n=52) and children without fever (n=396). The clinical characteristics, laboratory indicators, and outcomes of regimens for these children were analyzed with SPSS 16.0 software. Results: Children with initial fever had distinct clinical characteristics and laboratory indicators, including an age younger than two years, risk-organ involvement, accompanying hemophagocytic syndrome, and higher levels of cell-free DNA Conclusions: Among pediatric patients with LCH, those with initial fever exhibit more severe clinical symptoms and worse prognoses after first-line chemotherapy. Alternative strategies may mitigate fever-associated risk, and this possibility should be confirmed through prospective research.
Indexed as
feverLangerhans cell histiocytosis (LCH)prognosisprogressionprogression-free survival rate (PFS rate)
Identifiers
PMID42158684
PMCPMC13181683
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390